Skip to content
Protocol GuideFact-checked November 2026

Thymalin Protocol: Immune System Reset for Longevity

Thymalin is a thymus-derived peptide extract studied as a counter to thymic involution — the progressive shrinkage of the thymus driving immunosenescence. It is usually paired with Epithalon, and its human evidence comes from one research network.

Evidence strength

Level 3

Case-control study

Peer-reviewed refs

3

Reading time

11 min

Key Takeaways

  • The thymus gland shrinks by approximately 75% between ages 20 and 60. Thymalin is proposed to counter this; reversal of thymic involution in people is not shown in the studies cited here.
  • In a 6-8 year study of 266 older people, the Thymalin + Epithalamin combination was reported to cut mortality 2.5-fold versus controls (4.1-fold with annual courses for 6 years). The report comes from the group that developed the peptides and has not been independently repeated.
  • Community protocol: 10mg/day subcutaneous for 10 days, twice yearly, often in the same window as Epithalon. The published abstracts of the human studies do not state a dose.
  • Thymalin is contraindicated in autoimmune diseases and with immunosuppressive medications — it amplifies immune activity.

The Thymus: The Organ Nobody Talks About

The immune system has a master training organ: the thymus. Located in the chest behind the sternum, it is where T-lymphocyte precursors from bone marrow travel to mature into functional immune cells. It is the organ that teaches T-cells to distinguish self from non-self — the fundamental capacity that prevents both infection and autoimmunity.

The thymus's central importance makes what happens to it with age all the more consequential. Starting around puberty, the thymus begins a process of involution — progressive replacement of functional thymic tissue with fat. By age 40, the thymus has lost approximately 50% of its original mass. By age 60, that figure reaches 75%.

The result is immunosenescence: reduced naive T-cell output, impaired vaccine response, increasing proportion of dysfunctional exhausted T-cells, and reduced cancer immunosurveillance. Many researchers now consider thymic involution a primary driver of age-related disease burden.

The Two-System Theory

The central hypothesis of the St. Petersburg group that developed both peptides proposes that biological ageing is governed by two master regulatory systems:

  1. The neuroendocrine system — regulated by the pineal gland (targeted by Epithalon)
  2. The immune system — regulated by the thymus (targeted by Thymalin)

The practical implication: treating only one system leaves the other in an aged state, limiting the benefit. The combination of Epithalon + Thymalin simultaneously addresses both master systems — the cohort study tested each peptide alone and the two together.

[1]

The 266-Person Mortality Study

The most significant clinical evidence involves 266 elderly and older people followed for 6-8 years, with the peptides given during the first 2-3 years. Reported mortality fell 2.0-2.1-fold with Thymalin, 1.6-1.8-fold with Epithalamin, and 2.5-fold with the two combined versus controls. In a separate group given both peptides annually for 6 years, mortality was reported 4.1-fold lower.

This is extraordinary data. For context: most pharmaceutical interventions in elderly populations are considered significant if they produce a 20-30% mortality reduction. Alongside the mortality figures, the authors reported a 2.0-2.4-fold drop in acute respiratory illness and fewer clinical manifestations of ischaemic heart disease, hypertension and osteoporosis.

The caveats: the effect sizes are far larger than anything seen in comparable geroprotection research, and the report comes from a single group. The Oxford Level is therefore 3, not 1. The research was conducted by the same group that developed the compounds. Independent replication would substantially strengthen the evidence base.

[1]

The combined thymalin and epithalon course, graded to this evidence and with monitoring and stop rules, is laid out in The Bio-Clock Reset Protocol.

Mechanism of Action

Thymopoiesis restoration: Thymalin stimulates the proliferation and maturation of T-cell precursors in the thymic cortex, increasing the output of naive T-cells into peripheral circulation.

T-cell subset normalisation: Restores the CD4+/CD8+ ratio, which becomes dysregulated with age (too many exhausted memory cells, too few naive cells capable of responding to new antigens).

Cytokine regulation: Normalises the production of thymic hormones (thymosin, thymulin, thymopoetin) that regulate T-cell maturation throughout the body.

Thymic activity: In rats, low-dose Thymalin increased lymphoproliferative activity and the content of tissue basophils and plasmocytes in the thymic lobules, alongside an antitumour effect in a transplanted sarcoma model.

[3]

The Protocol

Synchronise with Epithalon cycles:

DayEpithalonThymalin
Days 1-1010mg SC daily10mg SC daily
Days 11+RestRest

This is the community convention, not a trial dose: the published abstracts of the human studies do not state one. Running both peptides in the same window also means a side effect cannot be attributed to either; The Bio-Clock Reset Protocol explains why separate windows are the safer design.

Both peptides are injected subcutaneously each morning during the 10-day cycle. Most practitioners rotate between left and right lower abdominal quadrants.

Annual schedule: Two cycles per year — spring (March-April) and autumn (September-October). This timing is a community convention.

Monitoring: Consider tracking immune function markers before and after cycles: complete blood count with differential, NK cell activity (if accessible), and inflammatory markers (hs-CRP, IL-6).

Scientific References

  1. [1]
    Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life — Neuro Endocrinology Letters (2003)Oxford 2b
    PMID 14523363
  2. [2]
    Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results (in Russian) — Advances in Gerontology (2013)Oxford 4
    PMID 24003726
  3. [3]
    Zhukova GV, Schikhlyarova AI, Barteneva TA, et al.. Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo — Bulletin of Experimental Biology and Medicine (2018)Oxford 5
    PMID 29797130

Follow us on Google Search

Add BiohackingHub as a preferred source to see more of our research in Google results.

Ad slot available · 728×90Advertise here

Related protocols

Partner with BiohackingHub

Editorial placements, sponsorships, and product features for evidence-minded brands.

Partnership opportunities →